4-41a-602. Cannabis product — Labeling and child-resistant packaging.
(1)
For any cannabis product that a cannabis processing facility processes or produces and for any raw cannabis that the facility packages, the facility shall:
Terms Used In Utah Code 4-41a-602
Appeal: A request made after a trial, asking another court (usually the court of appeals) to decide whether the trial was conducted properly. To make such a request is "to appeal" or "to take an appeal." One who appeals is called the appellant.
Artificially derived cannabinoid: means a chemical substance that is created by a chemical reaction that changes the molecular structure of any chemical substance derived from the cannabis plant. See Utah Code 4-41a-102
Process: means a writ or summons issued in the course of a judicial proceeding. See Utah Code 68-3-12.5
Qualified medical provider: means the same as that term is defined in Section 26B-4-201. See Utah Code 4-41a-102
Recommending medical provider: means the same as that term is defined in Section 26B-4-201. See Utah Code 4-41a-102
Total composite tetrahydrocannabinol: means all detectable forms of tetrahydrocannabinol. See Utah Code 4-41a-102
United States: includes each state, district, and territory of the United States of America. See Utah Code 68-3-12.5
(a)
label the cannabis or cannabis product with a label that:
(i)
clearly and unambiguously states that the cannabis product or package contains cannabis;
(ii)
clearly displays the amount of total composite tetrahydrocannabinol, cannabidiol, and any known cannabinoid that is greater than 1% of the total cannabinoids contained in the cannabis or cannabis product as determined under Subsection 4-41a-701(4);
(iii)
has a unique identification number that:
(A)
is connected to the inventory control system; and
(B)
identifies the unique cannabis product manufacturing process the cannabis processing facility used to manufacture the cannabis product;
(iv)
identifies the cannabinoid extraction process that the cannabis processing facility used to create the cannabis product;
(v)
does not display an image, word, or phrase that the facility knows or should know appeals to children; and
(vi)
discloses each active or potentially active ingredient, in order of prominence, and possible allergen; and
(b)
package the raw cannabis or cannabis product in a medicinal dosage form in a container that:
(i)
is tamper evident and tamper resistant;
(ii)
does not appeal to children;
(iii)
does not mimic a candy container;
(iv)
complies with child-resistant effectiveness standards that the United States Consumer Product Safety Commission establishes;
(v)
includes a warning label that states:
(A)
for a container labeled before July 1, 2021, “WARNING: Cannabis has intoxicating effects and may be addictive. Do not operate a vehicle or machinery under its influence. KEEP OUT OF REACH OF CHILDREN. This product is for medical use only. Use only as directed by a qualified medical provider.”;
(B)
for a container labeled on or after July 1, 2021, “WARNING: Cannabis has intoxicating effects and may be addictive. Do not operate a vehicle or machinery under its influence. KEEP OUT OF REACH OF CHILDREN. This product is for medical use only. Use only as directed by a recommending medical provider.”; or
(C)
for a container labeled on or after January 1, 2024, “WARNING: Cannabis has intoxicating effects, may be addictive, and may increase risk of mental illness. Do not operate a vehicle or machinery under its influence. KEEP OUT OF REACH OF CHILDREN. This product is for medical use only. Use only as directed by a recommending medical provider.”; and
(vi)
for raw cannabis or a cannabis product sold in a vaporizer cartridge labeled on or after May 3, 2023, includes a warning label that states:
(A)
“WARNING: Vaping of cannabis-derived products has been associated with lung injury.”; and
(B)
“WARNING: Inhalation of cannabis smoke has been associated with lung injury.”.
(2)
For any cannabis or cannabis product that the cannabis processing facility processes into a gelatinous cube, gelatinous rectangular cuboid, or lozenge in a cube or rectangular cuboid shape, the facility shall:
(a)
ensure that the label described in Subsection (1)(a) does not contain a photograph or other image of the content of the container; and
(b)
include on the label described in Subsection (1)(a) a warning about the risks of over-consumption.
(3)
For any cannabis product that contains an artificially derived cannabinoid, the cannabis processing facility shall ensure that the label clearly:
(a)
identifies each artificially derived cannabinoid; and
(b)
identifies that each artificially derived cannabinoid is an artificially derived cannabinoid.
complies with the requirements of this section; and
(B)
ensures inclusion of a pharmacy label; and
(ii)
additional requirements on packaging for cannabis and cannabis products to ensure safety and product quality; and
(b)
may make rules to further define standards regarding images, words, phrases, or containers that may appeal to children under Subsection (1)(a)(v) or (1)(b)(ii).
